Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial.

Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R.

Scand J Gastroenterol. 2011 Jun;46(6):663-72. doi: 10.3109/00365521.2011.565066. Epub 2011 Mar 28.

PMID:
21443416
2.

Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.

Ringel-Kulka T, Palsson OS, Maier D, Carroll I, Galanko JA, Leyer G, Ringel Y.

J Clin Gastroenterol. 2011 Jul;45(6):518-25. doi: 10.1097/MCG.0b013e31820ca4d6.

3.

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.

Guglielmetti S, Mora D, Gschwender M, Popp K.

Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x. Epub 2011 Mar 21.

4.

A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.

Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ.

J Clin Gastroenterol. 2011 Sep;45(8):679-83. doi: 10.1097/MCG.0b013e318204593e. Erratum in: J Clin Gastroenterol. 2011 Oct;45(9):838.

PMID:
21301358
5.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group.

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

6.

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.

Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y.

Gut Pathog. 2010 Dec 9;2(1):19. doi: 10.1186/1757-4749-2-19.

7.

Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis.

Garrett WS, Gallini CA, Yatsunenko T, Michaud M, DuBois A, Delaney ML, Punit S, Karlsson M, Bry L, Glickman JN, Gordon JI, Onderdonk AB, Glimcher LH.

Cell Host Microbe. 2010 Sep 16;8(3):292-300. doi: 10.1016/j.chom.2010.08.004.

8.

A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes.

Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L.

Gastroenterology. 2010 Dec;139(6):1844-1854.e1. doi: 10.1053/j.gastro.2010.08.049. Epub 2010 Oct 8.

PMID:
20816835
9.

Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas.

Shen XJ, Rawls JF, Randall T, Burcal L, Mpande CN, Jenkins N, Jovov B, Abdo Z, Sandler RS, Keku TO.

Gut Microbes. 2010 May-Jun;1(3):138-47. doi: 10.4161/gmic.1.3.12360. Epub 2010 May 13.

10.

Assessing gut microbial diversity from feces and rectal mucosa.

Durbán A, Abellán JJ, Jiménez-Hernández N, Ponce M, Ponce J, Sala T, D'Auria G, Latorre A, Moya A.

Microb Ecol. 2011 Jan;61(1):123-33. doi: 10.1007/s00248-010-9738-y. Epub 2010 Aug 24.

PMID:
20734040
11.

Treating irritable bowel syndrome with probiotics: the evidence.

Parkes GC, Sanderson JD, Whelan K.

Proc Nutr Soc. 2010 May;69(2):187-94. doi: 10.1017/S002966511000011X. Epub 2010 Mar 18. Review.

PMID:
20236566
12.

Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.

Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A.

BMC Gastroenterol. 2009 Dec 17;9:95. doi: 10.1186/1471-230X-9-95.

13.

Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.

Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A.

World J Gastroenterol. 2009 Dec 21;15(47):5936-45.

14.

Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome.

Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S.

Neurogastroenterol Motil. 2010 May;22(5):512-9, e114-5. doi: 10.1111/j.1365-2982.2009.01427.x. Epub 2009 Nov 10.

PMID:
19903265
15.

A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.

Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR.

Dig Dis Sci. 2010 Feb;55(2):392-7. doi: 10.1007/s10620-009-0934-x. Epub 2009 Aug 20.

PMID:
19693670
16.

The burden of IBS: looking at metrics.

Spiegel BM.

Curr Gastroenterol Rep. 2009 Aug;11(4):265-9. Review.

PMID:
19615301
17.

Alterations in the intestinal microbiota and functional bowel symptoms.

Ringel Y, Carroll IM.

Gastrointest Endosc Clin N Am. 2009 Jan;19(1):141-50, vii. doi: 10.1016/j.giec.2008.12.004. Review.

PMID:
19232285
18.

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review.

Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM.

Gut. 2010 Mar;59(3):325-32. doi: 10.1136/gut.2008.167270. Epub 2008 Dec 17. Review.

PMID:
19091823
19.

Comparative analysis of human gut microbiota by barcoded pyrosequencing.

Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L.

PLoS One. 2008 Jul 30;3(7):e2836. doi: 10.1371/journal.pone.0002836.

20.

Evolution of mammals and their gut microbes.

Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, Schlegel ML, Tucker TA, Schrenzel MD, Knight R, Gordon JI.

Science. 2008 Jun 20;320(5883):1647-51. doi: 10.1126/science.1155725. Epub 2008 May 22. Erratum in: Science. 2008 Nov 21;322(5905):1188.

Supplemental Content

Support Center